Here’s what happens when you stop taking Ozempic, Mounjaro

The explosive growth of GLP-1 receptor agonists—particularly Ozempic (semaglutide) and Mounjaro (tirzepatide)—has created a pharmaceutical phenomenon with significant implications for European investors with exposure to African healthcare markets. But emerging clinical evidence reveals a critical complication: rapid weight regain and metabolic rebound when patients discontinue these medications, a reality that demands serious portfolio reassessment.

When GLP-1 drugs work, they work remarkably well. By mimicking glucagon-like peptide-1, they suppress appetite signals in the brain while improving insulin sensitivity, leading to sustained weight loss in 60-70% of users. However, the mechanism reveals an uncomfortable truth: these medications don't retrain the body's metabolic set point. They mask the underlying problem temporarily. Once treatment stops, the neurochemical appetite suppression vanishes, and patients experience what many describe as "food noise" returning—the constant, intrusive awareness of hunger that they'd forgotten existed.

Clinical studies demonstrate that without continued treatment, patients regain approximately 80% of lost weight within 12 months of discontinuation. This creates a permanent dependency model fundamentally different from traditional pharmaceuticals. A patient on antihypertensives might eventually discontinue and maintain some benefit; a GLP-1 user cannot. The business implication is extraordinary: Novo Nordisk, Eli Lilly, and Roche have built multi-decade revenue streams on perpetual patient enrollment.

For European investors, this rebound mechanism presents both opportunity and risk. The positive thesis is straightforward: chronic treatment means recurring revenue. A patient starting Ozempic at age 45 becomes a 40-year customer if compliance holds. Yet the rebound creates market fragility. First, it ensures persistent dropout rates—patients who cannot sustain costs (€800-1,200 monthly out-of-pocket in many EU markets) face painful weight regain, driving them toward competing products or alternative interventions. Second, it attracts regulatory scrutiny; governments question whether perpetual, expensive weight-loss drugs represent good value in healthcare systems already strained by chronic disease management.

In African markets, this dynamic intensifies. With limited healthcare infrastructure and pricing pressure, GLP-1 penetration remains constrained to upper-income segments in South Africa, Egypt, and Nigeria. The rebound effect creates a two-tier system: wealthy patients sustaining treatment indefinitely, while middle-income users cycle on and off, facing metabolic chaos each time. European pharmaceutical companies and investors in African distribution networks must account for lower lifetime patient value than Western markets suggest.

The broader market implication: the GLP-1 boom may have peaked. Semaglutide and tirzepatide market growth projections assumed sustained demand. But as rebound rates become public knowledge, patient hesitation will increase. Why start a drug you'll never stop? Alternative approaches—combination therapies, lower-dose maintenance regimens, or upstream metabolic interventions—will fragment the market. Companies invested in premium positioning around these drugs face pressure.

For European investors in African healthcare platforms, diagnostics, or complementary obesity interventions, the rebound effect creates immediate opportunity. As GLP-1 drugs cycle through patient cohorts and real-world outcomes diverge from clinical trials, demand for sustainable alternatives—behavioral support, metabolic assessment, continuous monitoring platforms—will accelerate across African markets with growing middle-income populations.